Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-13

Clinical Trial Update: Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety and tolerability of preservative-free ophthalmic solution PRO-122 vs Krytantek Ofteno in glaucoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Krytantek Ofteno
  • PRO-122

Snippet

Sponsor: Laboratorios Sophia S.A de C.V. | Conditions: Glaucoma | Phase 1 | Status: COMPLETED | Results posted: 2019-12-13